Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.53 |
| ▸ | NAMPT | P43490 | 4/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9994777 | 0.92 | GPR119 (0.46) | GPR119NAMPTEPHX2NR1H2 | |
| SCHEMBL22835861 | 0.89 | GPR119 (0.56) | GPR119NAMPTUSP2SMN1; SMN2EPHX2 | |
| SCHEMBL24693734 | 0.87 | GPR119 (0.55) | GPR119NAMPTUSP2SMN1; SMN2NR1H2 | |
| SCHEMBL18586154 | 0.87 | GPR119 (0.54) | GPR119NAMPTUSP2SMN1; SMN2EPHX2 | |
| SCHEMBL25726262 | 0.87 | GPR119 (0.54) | GPR119NAMPTUSP2SMN1; SMN2EPHX2 | |
| SCHEMBL31586457 | 0.86 | GPR119 (0.59) | GPR119NAMPT | |
| SCHEMBL31250874 | 0.86 | GPR119 (0.51) | GPR119NAMPTUSP2SMN1; SMN2EPHX2 | |
| SCHEMBL21996980 | 0.85 | GPR119 (0.53) | GPR119NAMPTUSP2SMN1; SMN2EPHX2 | |
| SCHEMBL21997549 | 0.85 | NR1H2 (0.44) | GPR119NAMPTUSP2SMN1; SMN2EPHX2 | |
| SCHEMBL6749163 | 0.84 | GPR119 (0.52) | GPR119NAMPTUSP2SMN1; SMN2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12539295-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| EP-4680343-A1 | PROTEIN-PROTEIN INTERACTION STABILIZERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12486253-B2 | Therapeutics for the degradation of mutant BRAF | C4 THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4631940-A1 | COMPOUND TARGETING PAN-KRAS PROTEIN DEGRADATION AGENT AND USE THEREOF | Betta Pharmaceuticals Co., Ltd. (CN) | 2025-10-15 | — | — | EP | disclosed |
| EP-4587435-A1 | MODIFIED PROTEINS AND PROTEIN BINDERS AND DEGRADERS | Cullgen (Shanghai), Inc. (CN) | 2025-07-23 | — | — | EP | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| WO-2025103502-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| US-9359371-B2 | Bicyclic substituted pyrimidine compounds | Xuanzhu Pharma Co., Ltd. (CN) | 2016-06-07 | — | — | US | disclosed |
| US-20150232474-A1 | Bicyclic Substituted Pyrimidine Compounds | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2015-08-20 | — | — | US | disclosed |
| EP-2886540-A1 | BICYCLIC SUBSTITUTED PYRIMIDINE COMPOUNDS | Xuanzhu Pharma Co., Ltd. (CN) | 2015-06-24 | — | — | EP | disclosed |
| CN-104487434-A | Bicyclic substituted pyrimidine compounds | XUANZHU PHARMA CO LTD | 2015-04-01 | — | — | CN | disclosed |
| US-8889702-B2 | Derivatives of azaspiranyl-alkylcarbamates of 5-member heterocyclic compounds, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-11-18 | — | — | US | disclosed |
| EP-2519526-B1 | TRICYCLIC COMPOUNDS FOR USE AS KINASE INHIBITORS | CT NAC INVESTIGACIONES ONCOLOGICAS CNIO (ES) | 2014-03-26 | — | — | EP | disclosed |
| US-20130065881-A1 | Tricyclic Compounds for Use as Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (ES) | 2013-03-14 | — | — | US | disclosed |
| EP-2519526-A1 | TRICYCLIC COMPOUNDS FOR USE AS KINASE INHIBITORS | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2012-11-07 | — | — | EP | disclosed |
| US-20110319381-A1 | DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-12-29 | — | — | US | disclosed |
| WO-2011080510-A1 | TRICYCLIC COMPOUNDS FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | GPR119 1443/4885NAMPT 3507/4885USP2 740/4885 |
| US-12486253-B2 | Therapeutics for the degradation of mutant BRAF | BRAF, NRAS, KRAS | GPR119 4442/4885NAMPT 819/4885USP2 673/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GPR119 2426/4885NAMPT 1694/4885USP2 141/4885 |
| US-12539295-B2 | IRAK degraders and uses thereof | IRAK2, IRAK4, IRAK3 | GPR119 812/4885NAMPT 2987/4885USP2 551/4885 |
| US-20130065881-A1 | Tricyclic Compounds for Use as Kinase Inhibitors | PIM1, PIM2, PIM3 | GPR119 1305/4885NAMPT 3519/4885USP2 3646/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | GPR119 932/4885NAMPT 2728/4885USP2 684/4885 |
| US-20150232474-A1 | Bicyclic Substituted Pyrimidine Compounds | DPYD, UMPS, TYMP | GPR119 959/4885NAMPT 181/4885USP2 4361/4885 |
| US-20110319381-A1 | DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | PRMT9, IDH3B, DHFR | GPR119 1390/4885NAMPT 54/4885USP2 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.